Medytox Overview

  • Year Founded
  • 2000

Year Founded

  • Status
  • Public

  • Employees
  • 761

Employees

  • Stock Symbol
  • 086900

Stock Symbol

  • Investments
  • 15

  • Share Price
  • $51.83
  • (As of Friday Closing)

Medytox General Information

Description

Medy-Tox Inc. is a Korea-based company engaged in the development, manufacture, and marketing of biopharmaceuticals. The company's main product is type-A botulium toxin biopharmaceuticals which are used as remedies for blepharospasms, hemifacial spasms, eye wrinkles, hyperhidrosis diseases and infantile cerebral palsy.

Contact Information

Website
www.medytox.com
Ownership Status
Publicly Held
Financing Status
Formerly PE-Backed
Corporate Office
  • 626 Teheran-ro, Medytox Building, Daechi-dong
  • Gangnam-gu
  • Seoul, Gangnam 06175
  • South Korea
+82
Primary Industry
Pharmaceuticals
Other Industries
Other Pharmaceuticals and Biotechnology
Stock Exchange
KRX
Vertical(s)
Corporate Office
  • 626 Teheran-ro, Medytox Building, Daechi-dong
  • Gangnam-gu
  • Seoul, Gangnam 06175
  • South Korea
+82

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Medytox Stock Performance

As of 20-Nov-2026, Medytox’s stock price is $51.83. Its current market cap is $335M with 6.46M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$51.83 $54.79 $45.53 - $98.58 $335M 6.46M 24K $1.57

Medytox Financials Summary

As of 30-Jun-2026, Medytox has a trailing 12-month revenue of $173M.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 392,180 566,557 603,649 1,289,155
Revenue 173,006 173,764 167,558 169,124
EBITDA 5,346 18,202 28,041 24,984
Net Income 10,556 11,660 12,426 7,461
Total Assets 370,618 403,995 417,634 474,612
Total Debt 80,771 53,215 55,207 64,275
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Medytox Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Medytox‘s full profile, request access.

Request a free trial

Medytox Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Medy-Tox Inc. is a Korea-based company engaged in the development, manufacture, and marketing of biopharmaceuticals. The
Pharmaceuticals
Seoul, South Korea
761 As of 2025

Tarrytown, NY
 

Tokyo, Japan
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Medytox Competitors (20)

One of Medytox’s 20 competitors is Regeneron Pharmaceuticals, a Formerly VC-backed company based in Tarrytown, NY.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Regeneron Pharmaceuticals Formerly VC-backed Tarrytown, NY
Astellas Pharma Corporation Tokyo, Japan
Genzyme Ireland Corporation Kilmeaden, Ireland
Biocon Biologics Formerly PE-Backed Bengaluru, India
Pfizer Pakistan Corporation Karachi, Pakistan
You’re viewing 5 of 20 competitors. Get the full list »

Medytox Patents

Medytox Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026173467-A1 Kit for detecting anti-botulinum toxin antibody and method for diagnosing and treating patients with secondary non-responsiveness to botulinum toxin using same Pending 14-Feb-2025
WO-2026151300-A1 Microorganism having hyaluronic acid-producing ability, variant thereof, method for producing hyaluronic acid using same, medium composition for microorganism, and method for producing hyaluronic acid using same Pending 10-Jan-2025
WO-2026127707-A1 Injectable composition for skin texture improvement and/or skin moisturization, comprising gamma-polyglutamic acid Pending 13-Dec-2024
WO-2026101337-A1 Composition including crosslinked polynucleotide as active ingredient Pending 07-Nov-2024
WO-2025249959-A1 Fusion protein and use thereof Pending 30-May-2024 C07K14/70571
To view Medytox’s complete patent history, request access »

Medytox Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Medytox Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Medytox‘s full profile, request access.

Request a free trial

Medytox Investments & Acquisitions (15)

Medytox’s most recent deal was a Later Stage VC with Liflex Science for . The deal was made on 10-Nov-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Liflex Science 10-Nov-2026 Later Stage VC Biotechnology
Aigen Sciences 11-Jul-2025 Early Stage VC Drug Delivery
Aigen Sciences 04-Oct-2022 Seed Round Drug Delivery
Lysentech 22-Dec-2021 Early Stage VC Drug Discovery
Evolus 01-Sep-2021 Secondary Transaction - Private Pharmaceuticals
You’re viewing 5 of 15 investments and acquisitions. Get the full list »

Medytox ESG

Risk Overview

Risk Rating

Updated November, 08, 2026

32.87 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Medytox’s complete esg history, request access »

Medytox Exits (1)

Medytox’s most recent exit was on 28-Jul-2021 from Cellapeutics Bio. The exit was categorized as with 5 buyers.

Company Name Exit Date Exit Type Exit Size Status Buyers
Cellapeutics Bio 28-Jul-2021 Completed
  • 5 buyers
To view Medytox’s complete exits history, request access »

Medytox Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
Medytox Venture Investment Seoul, South Korea 2017

Medytox FAQs

  • When was Medytox founded?

    Medytox was founded in 2000.

  • Where is Medytox headquartered?

    Medytox is headquartered in Seoul, South Korea.

  • What is the size of Medytox?

    Medytox has 761 total employees.

  • What industry is Medytox in?

    Medytox’s primary industry is Pharmaceuticals.

  • Is Medytox a private or public company?

    Medytox is a Public company.

  • What is Medytox’s stock symbol?

    The ticker symbol for Medytox is 086900.

  • What is the current stock price of Medytox?

    As of 20-Nov-2026 the stock price of Medytox is $51.83.

  • What is the current market cap of Medytox?

    The current market capitalization of Medytox is $335M.

  • What is Medytox’s current revenue?

    The trailing twelve month revenue for Medytox is $173M.

  • Who are Medytox’s competitors?

    Regeneron Pharmaceuticals, Astellas Pharma, Genzyme Ireland, Biocon Biologics, and Pfizer Pakistan are some of the 20 competitors of Medytox.

  • What is Medytox’s annual earnings per share (EPS)?

    Medytox’s EPS for 12 months was $1.57.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process